A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles-Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Marc Vidal, Vicente Peg, Xavier Serres-CréixamsGraham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T. Rubio, Rodrigo Dientsmann, J. Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean Yves Masson, Stefano Cairo, Jean Gabriel Judde, Mark J. O'Connor, Orland Díez, Judith Balmaña, Violeta Serra

Research output: Contribution to journalArticlepeer-review

204 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences